OnKure Therapeutics to Present Preliminary Data From PIKture-01 Trial of OKI-219 at SABCS 2024
OnKure Therapeutics to Present Preliminary Data From PIKture-01 Trial of OKI-219 at SABCS 2024
The investor call will be held on Tuesday, December 10, 2024, at 7:00 a.m. CT (8:00 a.m. ET).OnKure Therapeutics will present preliminary data from the OKI-219 trial at SABCS on December 12, 2024.
OnKure Therapeutics將於2024年12月12日在SABCS上展示OKI-219試驗的初步數據。
Quiver AI Summary
Quiver AI 概要
OnKure Therapeutics, Inc. has announced that selected posters, including preliminary data from their PIKture-01 trial of OKI-219, will be presented at the upcoming 2024 San Antonio Breast Cancer Symposium (SABCS). Key details of the trial, which focuses on a mutant-selective inhibitor for advanced solid tumors, will be discussed in an investor call scheduled for December 10, 2024, at 7:00 a.m. CT, moving from the previously planned date of December 13. The posters will showcase findings related to OKI-219's effectiveness, with presentations on December 12. OnKure's ongoing research aims to develop targeted therapies for cancer, with OKI-219 as a lead candidate, highlighting their commitment to addressing underserved cancer types. Further details and updates will be made available on their website following the symposium.
OnKure Therapeutics, Inc.宣佈，選定的海報，包括其OKI-219的PIKture-01試驗的初步數據，將在即將舉行的2024年聖安東尼奧乳腺癌研討會（SABCS）上展示。該試驗的關鍵細節集中在針對晚期實體腫瘤的突變選擇性抑制劑，將在2024年12月10日上午7:00 CT的投資者電話會議中討論，該會議已從原定的12月13日改爲此日。海報將展示與OKI-219有效性相關的發現，並於12月12日進行展示。OnKure正在進行的研究旨在開發癌症的靶向治療，以OKI-219作爲主要候選藥物，凸顯其致力於解決服務不足的癌症類型。研討會後，進一步的細節和更新將在其網站上發佈。
Potential Positives
潛在的積極因素
- OnKure Therapeutics is presenting preliminary data from its first-in-human PIKture-01 trial of OKI-219 at the prestigious San Antonio Breast Cancer Symposium, highlighting its innovative approach in oncology.
- The company is holding an investor call to review this new data, indicating its commitment to transparency and investor engagement.
- OKI-219 is positioned as a potentially significant treatment option for advanced solid tumors, which could enhance OnKure's profile in the biopharmaceutical industry.
- The poster presentations will include additional data on the efficacy of OKI-219 with standard of care therapies in mutant breast cancer models, suggesting promising research outcomes.
- OnKure Therapeutics正在著名的聖安東尼奧乳腺癌研討會上展示其首個人體PIKture-01試驗OKI-219的初步數據，突顯其在腫瘤學中的創新方法。
- 公司正在舉行投資者電話會議，以審查這些新數據，表明其對透明度和投資者參與的承諾。
- OKI-219被定位爲針對晚期實體腫瘤的潛在重要治療選擇，這可能增強OnKure在生物製藥行業的形象。
- 海報展示將包括關於OKI-219在突變乳腺癌模型中與標準治療組合的有效性的附加數據，表明研究結果前景可喜。
Potential Negatives
潛在負面因素
- Changing the date of the investor call from December 13 to December 10 may indicate urgency or concern regarding the preliminary data, which could raise questions about the robustness of the findings.
- The need to publish preliminary data from the clinical trial could suggest that definitive results have not yet been achieved, potentially undermining investor confidence.
- Investors may view the reliance on forward-looking statements as a sign of risk and uncertainty regarding the company's future prospects and the development of their product candidates.
- 將投資者電話會議的日期從12月13日更改爲12月10日可能表明對初步數據的緊迫性或擔憂，這可能引發對發現的穩健性的問題。
- 發佈臨牀試驗的初步數據可能表明尚未獲得確鑿的結果，這可能會削弱投資者的信心。
- 投資者可能將對前瞻性聲明的依賴視爲對公司未來前景和產品候選開發的風險和不確定性的標誌。
FAQ
常見問題
What is OnKure Therapeutics announcing?
OnKure Therapeutics正在宣佈什麼？
OnKure is announcing poster presentations and an investor call regarding the preliminary data from the PIKture-01 trial of OKI-219.
OnKure正在宣佈關於OKI-219的PIKture-01試驗的初步數據的海報展示和投資者電話會議。
When will the investor call take place?
投資者電話會議將在什麼時候進行？
The investor call will be held on Tuesday, December 10, 2024, at 7:00 a.m. CT (8:00 a.m. ET).
投資者電話會議將於2024年12月10日星期二上午7:00（中央時間）舉行（上午8:00東部時間）。
How can I access the presentation of the PIKture-01 trial?
我該如何訪問PIKture-01試驗的演示？
The presentation can be accessed through a conference call or webcast available on OnKure's website.
該演示可以通過電話會議或在OnKure網站上提供的網絡直播訪問。
What is the focus of the PIKture-01 clinical trial?
PIKture-01臨牀試驗的重點是什麼？
The PIKture-01 trial focuses on OKI-219 as a treatment for advanced solid tumors and advanced breast cancer.
PIKture-01試驗的重點是將OKI-219作爲治療愛文思控股的晚期實體瘤和晚期乳腺癌的方案。
Where can I find more information about OnKure and its projects?
我在哪裏可以找到有關OnKure及其項目的更多信息？
More information about OnKure and its ongoing projects can be found on their official website at .
有關OnKure及其正在進行的項目的更多信息可以在他們的官方網站上找到。
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
免責聲明：這是由GlobeNewswire分發的新聞稿的人工智能生成摘要。用於總結這份稿件的模型可能會出錯。請在這裏查看完整發佈。
Full Release
完整發佈
BOULDER, Colo., Nov. 25, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that posters selected for presentation at the 2024 San Antonio Breast Cancer Symposium (SABCS), including the poster presenting the preliminary data from the Company's first-in-human PIKture-01 trial of OKI-219, will be published to the symposium's virtual meeting platform for registered attendees on December 10
th
.
科羅拉多州博爾德，2024年11月25日（環球新聞網）-- OnKure Therapeutics, Inc.（納斯達克：OKUR）是一家專注於開發腫瘤學新型精準藥物的臨牀階段生物製藥公司，今天宣佈，選定的海報將於2024年聖安東尼奧乳腺癌研討會（SABCS）上展示，包括展示公司首個人體試驗PIKture-01的OKI-219初步數據的海報，將於12月10日在研討會的虛擬會議平台上發佈給註冊與會者。
th
.
OnKure will now hold its investor call to review preliminary data from the PIKture-01 study of OKI-219 on Tuesday, December 10, 2024 at 7:00 a.m. CT (8:00 a.m. ET). The Company had previously announced the investor call would be held on Friday, December 13, 2024. To join the call, please dial 877-407-0789 (domestic), 201-689-8562 (international) and refer to conference ID 13750009. The call may also be accessed via webcast (
click here
) or from the Events page of the Investors section of the Company's website at
. A replay of the webcast will be available on OnKure's website for at least 30 days following the call.
OnKure將於2024年12月10日（星期二）上午7:00（中部時間）召開投資者電話會議，審查OKI-219的PIKture-01研究的初步數據（東部時間上午8:00）。公司之前宣佈投資者電話會議將於2024年12月13日（星期五）舉行。要加入電話會議，請撥打877-407-0789（國內）或201-689-8562（國際），並提及會議ID 13750009。電話會議還可以通過網絡直播訪問（
點擊這裏
）或通過公司網站投資者部分的活動頁面訪問，
該網絡直播的回放將在OnKure的網站上提供，至少保留30天。
In addition, today, SABCS published the full text from all regular abstracts on its website (
click here
). OnKure plans to include additional data in the posters being presented at SABCS, which will be made available on the Company's website after the poster is presented.
此外，今天，SABCS在其網站上發佈了所有常規摘要的完整文本（
點擊這裏
OnKure計劃在SABCS展示的海報中包含額外數據，海報展示後將會在公司網站上提供。
There are no changes to the planned in-person poster presentations at SABCS, which is taking place in San Antonio, Texas.
在德克薩斯州聖安東尼奧舉行的SABCS上，計劃中的現場海報展示沒有變化。
Poster presentation details:
Poster Title:
Preliminary results from PIKture-01, a First-in-Human Study of OKI-219, a mutant
selective inhibitor of PI3Kα
H1047R
, in mutant selected solid tumors including breast cancer
Author:
Alexander Spira, MD, PhD, et al.
Presentation ID:
P3-08-19
Poster Session:
Poster Session 3
Session Location:
Halls 2-3
Presentation Date/Time:
Thursday, December 12, 2024 12:30 PM to 2:00 PM CST
Abstract Number:
SESS-3634
海報展示詳情：
海報標題：
來自PIKture-01的初步結果，這是對OKI-219的一項首次人類研究，一種突變的
選擇性PI3Kα抑制劑
H1047R
, 針對突變選擇的固體腫瘤，包括乳腺癌
作者：
亞歷山大·斯皮拉，醫學博士，博士，等。
演示ID：
P3-08-19
海報環節：
海報環節 3
會議地點:
大廳 2-3
演講日期/時間:
2024年12月12日，星期四 12:30 PM 到 2:00 PM CST
摘要編號：
SESS-3634
Poster Title:
OKI-219 enhances activity of SOC therapies in double and triple combinations in pre-clinical PI3Kα
H1047R
mutant breast cancer models
Author:
Molly Taylor, PhD, et al.
Presentation ID:
P4-12-20
Poster Session:
Poster Session 4
Session Location:
Halls 2-3
Presentation Date/Time:
Thursday, December 12, 2024 05:30 PM to 7:00 PM CST
Abstract Number:
SESS-2240
海報標題:
OKI-219在臨牀前PI3Kα突變乳腺癌模型中增強SOC療法在雙重和三重組合中的活性
H1047R
突變乳腺癌模型
作者：
莫莉·泰勒，博士，等。
演示 ID：
P4-12-20
海報會議：
海報會議 4
會議地點：
展廳2-3
演示日期/時間：
2024年12月12日（星期四）下午5:30至7:00 CST
摘要編號：
SESS-2240
For more details about SABCS please visit:
.
有關SABCS的更多詳情，請訪問：
.
OKI-219 is being investigated in the PIKture-01 clinical trial. PIKture-01 is a first-in-human study of the PI3KαH1047R Mutant-Selective Inhibitor OKI-219 as monotherapy in participants with advanced solid tumors and in combination with endocrine therapy or HER2-Targeted Therapy in participants with advanced breast cancer. Additional information about PIKture-01 may be found at
, using Identifier: NCT06239467.
OKI-219正在PIKture-01臨牀試驗中進行調查。PIKture-01是關於PI3KαH1047R突變選擇性抑制劑OKI-219的首次人體研究，作爲單藥治療在晚期實體瘤參與者中，及與內分泌治療或HER2靶向治療聯用在晚期乳腺癌參與者中的應用。有關PIKture-01的更多信息請訪問
, 使用標識符: NCT06239467。
About OnKure
關於OnKure
OnKure is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using structure-based drug design platform, OnKure is building a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability. OnKure is currently developing OKI-219, a selective PI3Kα
H1047R
inhibitor, as its lead program. OnKure aims to become a leader in targeting oncogenic PI3Kα and has multiple programs designed to enable best-in-class targeting of this key oncogene.
OnKure是一家臨牀階段的生物製藥公司，專注於發現和開發最佳精準藥物，針對生物學驗證的癌症驅動因素，這些因素在現有療法中未得到充分滿足。利用結構基礎的藥物設計平台，OnKure正在構建一條腫瘤無關候選藥物的管道，旨在實現最佳的療效和耐受性。OnKure目前正在開發OKI-219，一種選擇性的PI3Kα抑制劑，作爲其主導項目。OnKure的目標是成爲針對致癌PI3Kα的領導者，並設計了多個項目以實現對這一關鍵腫瘤基因的最佳靶向。
H1047R
抑制劑，作爲其主導項目。OnKure的目標是成爲針對致癌PI3Kα的領導者，並設計了多個項目以實現對這一關鍵腫瘤基因的最佳靶向。
For more information about OnKure, visit us at
and follow us on LinkedIn.
關於OnKure的更多信息，請訪問我們的網站
並在LinkedIn上關注我們。
Forward-Looking Statements
前瞻性聲明
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future financial condition, results of operations, business strategy and plans, and objectives of management for future operations, as well as statements regarding industry trends, are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the potential of, and expectations regarding, OnKure's product candidates and programs, including OKI-219; OnKure's ability to advance additional programs; the expected milestones and timing of such milestones, including for OKI-219 and its discovery programs; and statements regarding OnKure's financial position, including its liquidity, cash runway and the sufficiency of its cash resources. In some cases, you can identify forward-looking statements by terminology such as "estimate," "intend," "may," "plan," "potentially" "will" or the negative of these terms or other similar expressions.
本新聞稿包含前瞻性聲明，這些聲明涉及重大風險和不確定性。除歷史事實聲明外，本新聞稿包含的所有聲明，包括關於我們未來財務狀況、運營結果、業務策略和計劃以及管理層未來運營目標的聲明，以及關於行業趨勢的聲明，均爲前瞻性聲明。這些前瞻性聲明包括但不限於，關於OnKure產品候選藥物和程序的潛力及預期，包括OKI-219；OnKure推進額外項目的能力；這些項目的預期里程碑及時間安排，包括OKI-219及其發現項目；以及關於OnKure財務狀況及其流動性、現金週轉及現金資源充足性的聲明。在某些情況下，您可以通過諸如「估計」、「打算」、「可能」、「計劃」、「潛在地」、「將」或這些術語的否定形式或其他類似表達來識別前瞻性聲明。
The company based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things, those risks described in the section entitled "Risk Factors" in documents that OnKure files from time to time with the Securities and Exchange Commission ("SEC"), including the final 424B3 proxy statement/prospectus filed with the SEC on August 26, 2024. These risks are not exhaustive. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this press release.
The company based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things, those risks described in the section entitled "Risk Factors" in documents that OnKure files from time to time with the Securities and Exchange Commission ("SEC"), including the final 424B3 proxy statement/prospectus filed with the SEC on August 26, 2024. These risks are not exhaustive. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors, nor CAN we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we CANnot guarantee future results, levels of activity, performance or achievements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this press release.
Contact:
聯繫：
Dan Ferry
LifeSci Advisors
daniel@lifesciadvisors.com
Dan Ferry
LifeSci顧問
daniel@lifesciadvisors.com
